Bank of America Securities analyst Jason Gerberry has reiterated their neutral stance on UTHR stock, giving a Hold rating today.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason Gerberry has given his Hold rating due to a combination of factors. The recent second-quarter results from United Therapeutics were largely as expected, with no significant surprises that would necessitate a change in the company’s forecasts. Despite the year-to-date stock weakness, which has been more pronounced than the broader market, the competitive pressures faced by the company are still uncertain in their impact.
Furthermore, while the company has provided updated timelines for its Phase 3 TETON-2 study in idiopathic pulmonary fibrosis (IPF), the data supporting Tyvaso’s efficacy in this area remains limited. Although there is potential for a significant upside if the data proves favorable, the current valuation appears reasonable. Gerberry maintains a neutral stance, awaiting more robust data on key catalysts, such as IPF and xenotransplantation, which carry higher risk profiles.
In another report released today, Wells Fargo also assigned a Hold rating to the stock with a $295.00 price target.
UTHR’s price has also changed moderately for the past six months – from $352.300 to $281.950, which is a -19.97% drop .